Total Voting Rights and Capital
In conformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc ("the Company") hereby notifies the market of the following:
The Company's issued share capital as at 30 September 2010 consisted of 5,667,896,232 Ordinary shares of 25p each with voting rights, of which 474,194,158 Ordinary shares are held in Treasury.
Therefore, the total number of voting rights in the Company is 5,193,702,074. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Services Authority's Disclosure and Transparency Rules.
S M Bicknell
Company Secretary
1 October 2010